A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
NCT ID: NCT06973291
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
600 participants
INTERVENTIONAL
2025-07-09
2026-07-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants will take one tablet daily of either zasocitinib or a matching placebo, along with one capsule daily of either over-encapsulated deucravacitinib or a matching placebo, for a duration of 16 weeks.
Participants will be in the study for up to 25 weeks, which includes screening period of up to 35 days, a 16-week treatment period, and a 4-week safety follow-up period.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Zasocitinib or Placebo
Participants will receive zasocitinib or matching placebo tablet, orally, once daily (QD) up to Week 16.
Zasocitinib
Zasocitinib tablets.
Placebo to match zasocitinib
Zasocitinib matching placebo tablets.
Deucravacitinib or Placebo
Participants will receive deucravacitinib 6 mg or matching placebo capsule, orally, QD up to Week 16.
Deucravacitinib
Deucravacitinib capsules.
Placebo to match deucravacitinib
Deucravacitinib matching placebo capsules.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zasocitinib
Zasocitinib tablets.
Deucravacitinib
Deucravacitinib capsules.
Placebo to match zasocitinib
Zasocitinib matching placebo tablets.
Placebo to match deucravacitinib
Deucravacitinib matching placebo capsules.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participant has stable plaque psoriasis, defined as no significant flare or change in morphology (as assessed by the investigator) in psoriasis, for \>=6 months before screening.
3. Participant has moderate-to-severe plaque psoriasis, as defined by a PASI score \>=12 and an sPGA score \>=3, at screening and Day 1.
4. Participant has plaque psoriasis covering \>=10 percent (%) of his or her total body surface area (BSA) at screening and Day 1.
5. Participant must be a candidate for phototherapy or systemic therapy.
Exclusion Criteria
1. Participant has evidence of nonplaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis). If a participant meets criteria for inclusion based on typical plaque psoriasis presentation, a limited amount of inverse psoriasis is not exclusionary.
2. Participant requires systemic treatment, other than nonsteroidal anti-inflammatory drugs, during the trial period for an immune related disease (for example, inflammatory bowel disease).
3. Participant has a history of excessive sun exposure, has used tanning booths within 4 weeks prior to Day 1, or is not willing to minimize natural and artificial sunlight exposure during the trial period. Use of sunscreen products and protective apparel is recommended when sun exposure cannot be avoided.
4. Participant has concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the trial assessments.
Recent/Concurrent Infectious Disease Exclusions:
5. Tuberculosis (TB):
1. Participant has history of active TB infection, regardless of treatment status.
2. Participant has signs or symptoms of active TB (including, but not limited to, chronic fever, chronic productive cough, night sweats, or weight loss) as judged by the investigator.
3. Participant has evidence of latent TB infection (LTBI) as evidenced by a positive QuantiFERON-TB Gold (QFT) result OR 2 indeterminate QFT results, and participant does not have documentation of appropriate LTBI prophylaxis or is not able or not willing to initiate appropriate LTBI prophylaxis.
4. Participant has had any imaging trial during or 6 months prior to screening, including x-ray, chest computed tomography, Magnetic Resonance Imaging (MRI), or other chest imaging suggesting evidence of current active or a history of active TB. X-ray is required for all participants regardless of QFT results unless the participant has had normal chest imaging in the 6 months prior to screening.
6. Herpes infections:
1. Participant has active herpes virus infection, including herpes zoster or herpes simplex 1 and 2 (demonstrated on physical examination and/or medical history) at screening or Day 1.
2. Participant has history of serious herpetic infection that includes any episode of disseminated disease, multidermatomal herpes zoster, herpes encephalitis, ophthalmic herpes, or recurrent herpes zoster (defined as 2 episodes within 2 years).
7. Nonherpetic viral diseases:
1. Participant has presence of Hepatitis C Virus (HCV) antibody and a positive confirmatory test result for HCV ribonucleic Acid (RNA) (nucleic acid test or Polymerase Chain Reaction \[PCR\]).
2. Participant has presence of positive Hepatitis B Surface Antigen (HBsAg+), or indeterminate HBsAg, presence of HBV deoxyribonucleic Acid (DNA) (regardless of serology), or positive anti-hepatitis B core antibody without concurrent positive hepatitis B surface antibody (Hepatitis B Core Antibody \[HBcAb\] positive and Hepatitis B Surface Antibody \[HBsAb\] negative).
3. Participant has positive results for Human Immunodeficiency Virus (HIV) by serology, regardless of viral load.
8. Other infectious diseases:
1. Participant has a history of active infection or febrile illness within 7 days prior to Day 1, as assessed by the investigator.
2. Participant has history of symptoms suggestive of systemic or invasive infection within 30 days prior to Day 1.
3. Participant has history of bacterial, viral, or fungal infection that required hospitalization or treatment with intravenous antimicrobial therapy within 8 weeks prior to Day 1 or oral antimicrobial therapy within 30 days prior to Day 1.
4. Participant has a history of chronic or recurrent bacterial disease, including but not limited to chronic pyelonephritis or cystitis, chronic bronchitis/pneumonitis, osteomyelitis, or chronic skin ulcerations/infections or fungal infections (except superficial onychomycosis).
5. Participant has a history of an infected joint prosthesis, unless that prosthesis has been removed or replaced at least 60 days prior to Day 1.
6. Participant has a history of opportunistic infections (for example, Pneumocystis jirovecii pneumonia, histoplasmosis, coccidiomycosis).
7. Participant had a bacterial infection within 60 days prior to Day 1 for which he or she did not receive treatment.
* Noninfectious Disorders Exclusions:
9. Participant has any clinically significant medical condition, evidence of an unstable clinical condition (for example, cardiovascular, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or immunologic), or vital signs/physical/laboratory/Electrocardiogram (ECG) abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of trial results. These include but are not limited to:
1. Participant has a history of known or suspected condition/illness that is consistent with compromised immunity, including but not limited to any identified congenital or acquired immunodeficiency, splenectomy.
2. Participant had a major surgery within 60 days prior to Day 1 or has a major surgery planned during the trial.
3. Participant has unstable, poorly controlled, or severe hypertension at screening, confirmed by 2 repeat assessments.
4. Participant has a history of Class III or IV congestive heart failure as defined by New York Heart Association criteria.
5. Participant has a history of cancer or lymphoproliferative disease, with the exception of successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix.
6. For participants with asthma, chronic obstructive pulmonary disease, or other pulmonary illnesses, participant has been hospitalized in the past 3 months, has ever required intubation for treatment, currently requires oral corticosteroids, or has required more than 1 course of oral corticosteroids within 6 months prior to Day 1.
7. Participant has any of the following cardiovascular disease history:
* A new diagnosis of atrial fibrillation or an episode of atrial fibrillation with rapid ventricular response or other dysrhythmia, nonacute cardiac hospitalization (for example, pacemaker implantation), pulmonary embolism, or deep venous thrombosis within the past 6 months prior to screening.
* Any history of cerebrovascular event, myocardial infarction, coronary stenting, or aorto-coronary bypass surgery. If, however, the investigator determines there are no suitable treatment alternatives available for the participant and it has been at least 6 months since the occurrence of any such event, the participant may enroll.
8. Participant has ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the participant if he or she participated in the trial, in the opinion of the investigator.
9. Participant has significant/uncontrolled psychiatric illness, in the opinion of the investigator.
10. Participant has a history of clinically significant drug or alcohol abuse within 12 months prior to Day 1.
* Prohibited Psoriasis Treatments Exclusions:
For the below prohibited psoriasis treatments, the washout period prior to Day 1 is within the time frame indicated or 5 half-lives, whichever is longer, regardless of whether they are prescribed for psoriasis or another condition:
10. Participant has received any of the following biologics or biosimilar versions within the time frame indicated:
1. Antibodies to interleukin (IL)-12/-23, IL-17, or IL-23 (for example, ustekinumab, secukinumab, tildrakizumab, ixekizumab, or guselkumab) within 6 months prior to Day 1.
2. Tumor Necrosis Factor (TNF) inhibitor(s) (for example, etanercept, adalimumab, infliximab, or certolizumab) within 2 months prior to Day 1.
3. Agents that modulate integrin pathways to impact lymphocyte trafficking (for example, natalizumab) or agents that modulate B cells or T cells (for example, alemtuzumab, abatacept, or visilizumab) within 3 months prior to Day 1.
4. Rituximab or other immune cell-depleting therapy within 6 months prior to Day 1.
11. Participant has used medicated shampoo and/or body wash, including formulations containing but not limited to salicylic acid, corticosteroids, coal tar, vitamin D3 analogues, or other compounds used for the management of psoriasis within 2 weeks prior to Day 1.
12. Participant has used any topical medication that could affect psoriasis presentation (including but not limited to corticosteroids, salicylic acid, urea, alpha- or beta-hydroxy acids, anthralin, retinoids, vitamin D analogues \[such as calcipotriol\], methoxsalen, trimethylpsoralen, calcineurin inhibitors \[for example, tacrolimus\], tapinarof, roflumilast, Janus kinase (JAK) inhibitors, or tar) within 2 weeks prior to Day 1.
13. Participant has used any systemic nonbiologic treatment that could affect psoriasis presentation (including oral, intravenous, intramuscular, intra-articular, intrathecal, or intralesional corticosteroids; oral retinoids; immunosuppressive/immunomodulating medication; methotrexate; azathioprine; 6-thioguanidine; mercaptopurine; mycophenolate mofetil; hydroxyurea; cyclosporine; 1,25-dihydroxyvitamin D3 analogues; psoralens; sulfasalazine; fumaric acid derivatives; JAK inhibitors; apremilast) within 4 weeks prior to Day 1, or 5 half-lives, whichever is longer. Note: Intranasal corticosteroids, inhaled corticosteroids, and eye and ear drops containing corticosteroids are permitted.
14. Participant has used leflunomide within 6 months prior to Day 1.
15. Participant has received phototherapy (including Ultraviolet B \[UV B\], Psoralen plus Ultraviolet A \[PUVA\], tanning beds, therapeutic sunbathing) or excimer laser within 4 weeks prior to Day 1.
16. Participant has used botanical preparations (for example, herbal supplements or traditional medicines, including traditional Chinese medicines derived from plants, minerals, or animals) intended to treat psoriasis or other immunological diseases within 4 weeks prior to Day 1.
17. Participant is currently being treated with oral antihistamines for any reason, with the exception of oral antihistamines that are administered at a stable dose for at least 4 weeks prior to Day 1. Note: Additional treatment with oral antihistamines may be permitted after discussion with the medical monitor.
18. Participant has any previous exposure to zasocitinib (also known as TAK-279 or NDI 034858) or other Tyrosine Kinase 2 (TYK2) inhibitors (including deucravacitinib), or participated in any trial that included a TYK2 inhibitor (for example, deucravacitinib, VTX958, GLPG3667, et cetera), unless participant has documentation of posttrial unblinding that confirms the participant did not receive a TYK2 inhibitor.
\- Other Prohibited Concomitant Medications Exclusions: For the below prohibited concomitant medications, where applicable, the washout period prior to Day 1 is within the time frame indicated or 5 half-lives, whichever is longer.
19. Participant has received lithium, antimalarials, or intramuscular gold therapy within 4 weeks prior to Day 1.
20. Participant is currently being treated with strong or moderate Cytochrome P450 3A4 (CYP3A4) inhibitors (such as itraconazole) or strong or moderate CYP3A4 inducers (such as rifampin, carbamazepine, or phenytoin), or has received strong or moderate CYP3A4 inhibitors or strong or moderate CYP3A4 inducers within 4 weeks or 5 half-lives of the inducer or inhibitor, whichever is longer, prior to Day 1, or is anticipated to require treatment with strong or moderate CYP3A4 inducers or inhibitors during the trial period.
Note: This includes consumption of food or beverages containing grapefruit and/or Seville oranges within 1 week of Day 1. Participants must be counseled to avoid food or beverages containing grapefruit and/or Seville oranges for the duration of the trial.
21. Participant has received any live-attenuated vaccine within 60 days prior to Day 1 or plans to receive a live-attenuated vaccine during the trial and up to 4 weeks after the last trial intervention administration.
Note: Non-live-attenuated vaccines or boosters for Coronavirus Disease 2019 (COVID-19) or influenza are permitted during the trial.
22. Participant received an investigational antibody or biologic therapy within 6 months prior to Day 1.
23. Participant received an investigational oral therapy within 3 months prior to Day 1.
24. Participant is currently receiving a nonbiological trial intervention or device or has received one within 4 weeks prior to Day 1.
25. Participant is currently enrolled in a clinical trial or anticipates enrollment in a clinical trial during the course of the trial.
\- Laboratory/Physical Exclusions:
26. Participant has any of the following laboratory values at the screening visit:
1. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values greater than (˃)3\*upper limit of normal (ULN).
2. Total Bilirubin (Tbili) (unconjugated and/or conjugated) ˃1.5\*ULN.
3. Hemoglobin less than (\<) 9.0 grams per deciliter (g/dL) (\<90.0 grams per liter \[g/L\]).
4. Absolute white blood cell (WBC) count \<3.0\*109/liters (L) (\<3000 per cubic millimeter \[/mm3\]).
5. Absolute neutrophil count of \<1.0\*109/L (\<1000/mm3).
6. Absolute lymphocytes count of \<0.5\*109/L (\<500/mm3).
7. Platelet count \<100\*109/L (\<100,000/mm3).
8. Thyroid-stimulating hormone outside the normal reference range AND free T4 or T3 outside the normal reference range.
9. Estimated creatinine clearance \<45 milliliters per minute (mL/min) based on the Cockcroft-Gault calculation.
10. Creatine phosphokinase (CPK) \> ULN. CPK may be repeated once; if repeat value is Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or lower (or \<=2.5\*ULN) and no higher than the initial value, participant remains eligible. Investigators should assess the participant for modulating factors, including concomitant medications or vigorous exercise, that may affect CPK levels.
27. Participant has any other significant laboratory abnormalities that, in the opinion of the investigator, might place the participant at unacceptable risk for participation in this trial.
28. Participant does not tolerate venipuncture or inability to be venipunctured.
\- Allergies and Adverse Drug Reactions Exclusions:
29. Participant has history of significant drug allergy (such as anaphylaxis).
30. Participant has a known or suspected allergy to zasocitinib or deucravacitinib or any of their components.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johnson Dermatology
Fort Smith, Arkansas, United States
Burke Pharmaceutical Research
Hot Springs, Arkansas, United States
Zenith Research, Inc.
Beverly Hills, California, United States
First OC Dermatology Research Inc.
Fountain Valley, California, United States
UNISON Clinical Trials (Shahram Jacobs md inc.)
Sherman Oaks, California, United States
Central Connecticut Dermatology, PLLC
Cromwell, Connecticut, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Direct Helpers Research Center
Hialeah, Florida, United States
San Marcus Research Clinic Inc
Miami Lakes, Florida, United States
Advanced Clinical Research Institute
Tampa, Florida, United States
Arlington Dermatology
Rolling Meadows, Illinois, United States
Endeavor Health Clinical Trials
Skokie, Illinois, United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
Lawrence J Green, MD LLC
Rockville, Maryland, United States
Henry Ford Health System
Detroit, Michigan, United States
JDR Dermatology Research, LLC
Las Vegas, Nevada, United States
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
Markowitz Medical PLLC dba OptiSkin Medical
New York, New York, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Bexley Dermatology Research - Probity - PPDS
Bexley, Ohio, United States
Apex Clinical Research Center, LLC - Canton
Canton, Ohio, United States
Apex Clinical Research Center, LLC - Mayfield Heights
Mayfield Heights, Ohio, United States
UPMC Department of Dermatology
Pittsburgh, Pennsylvania, United States
Goodlettsville Dermatology Research
Goodlettsville, Tennessee, United States
Arlington Research Center
Arlington, Texas, United States
Bellaire Dermatology Associates
Bellaire, Texas, United States
The University of Texas Health Science Center at Houston (UTHSC-H)
Bellaire, Texas, United States
Reveal Research Institute
Dallas, Texas, United States
San Antonio
San Antonio, Texas, United States
Texas Dermatology and Laser Specialists-San Antonio
San Antonio, Texas, United States
Houston Center for Clinical Research, LLC
Sugar Land, Texas, United States
Medical Centre Femiclinic EOOD
Sofia, Dianabad District, Bulgaria
Medical Center Unimed EOOD-Sevlievo
Sevlievo, Gabrovo, Bulgaria
Medical Center Asklepii OOD
Dupnitsa, Kyustendil, Bulgaria
Diagnostic and Consulting Center Aleksandrovska EOOD
Sofia, Sofia-Grad, Bulgaria
Medical Center Hera EOOD-Sofia
Sofia, Sofia-Grad, Bulgaria
Diagnostic Consultative Center XXVIII - Sofia - EOOD
Sofia, Sofia-Grad, Bulgaria
Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia
Sofia, Sofia-Grad, Bulgaria
Multiprofile Hospital For Active Treatment Dr Tota Venkova
Gabrovo, , Bulgaria
Diagnostic Consultative Center Sveti Georgi EOOD
Haskovo, , Bulgaria
Medical Center Medconsult Pleven - Lovech Branch
Lovech, , Bulgaria
Beacon Dermatology - Probity
Calgary, Alberta, Canada
VIDA Dermatology - Probity
Edmonton, Alberta, Canada
Enverus Medical Research - Probity
Surrey, British Columbia, Canada
Dr Chih-Ho Hong Medical Inc
Surrey, British Columbia, Canada
Wiseman Dermatology Research Inc.
Winnipeg, Manitoba, Canada
Brunswick Dermatology Centre - Probity
Fredericton, New Brunswick, Canada
Lima's Excellence In Allergy And Dermatology Research (Leader) Inc. - Probity
Hamilton, Ontario, Canada
Dermatrials Research
Hamilton, Ontario, Canada
Lynderm Research Inc - Probity
Markham, Ontario, Canada
North Bay Dermatology Center - Probity
North Bay, Ontario, Canada
The Centre for Clinical Trials Inc.
Oakville, Ontario, Canada
Skin Centre for Dermatology
Peterborough, Ontario, Canada
The Centre For Dermatology
Richmond Hill, Ontario, Canada
Alliance Clinical Trials
Waterloo, Ontario, Canada
XLR8 Medical Research
Windsor, Ontario, Canada
Siena Medical Research Corporation
Montreal, Quebec, Canada
Skinsense Medical Research
Saskatoon, Saskatchewan, Canada
Centre de Recherche Dermatologique du Quebec Metropolitain
Québec, , Canada
Nemocnice AGEL Novy Jicin a.s
Nový Jičín, Moravskoslezský kraj, Czechia
CCR Ostrava s.r.o.
Ostrava, Moravskoslezský kraj, Czechia
Dermskin s.r.o
Olomouc, Olomoucký kraj, Czechia
Pratia Brno s.r.o. - PRATIA - PPDS
Brno, South Moravian, Czechia
Pratia Pardubice
Pardubice, , Czechia
CLINTRIAL s.r.o.
Prague, , Czechia
Prof. MUDr. Petr Arenberger, DrSc. - CRC - PPDS
Prague, , Czechia
Praglandia s.r.o.
Prague, , Czechia
Office of Mireille Ruer-Mulard, MD
Martigues, Paca, France
Centre Hospitalier Le Mans
Le Mans, Sarthe, France
Hopital Charles Nicolle-1 Rue de Germont
Rouen, , France
Centre Hospitalier Universitaire de Saint Etienne
Saint-Etienne, , France
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan
Fukuoka University Hospital
Fukuoka, Fukuoka, Japan
Hino Dermatology Clinic
Fukutsu-shi, Fukuoka, Japan
JR Sapporo Hospital
Sapporo, Hokkaido, Japan
Investigational Product department
Sapporo, Hokkaido, Japan
Nippon Life Hospital
Osaka, Osaka, Japan
Investigational Product department Dermatology and Ophthalmology Kume Clinic
Sakai-shi, Osaka, Japan
Seikoukai Omi Medical Center
Kusatsu-shi, Shiga, Japan
Jichi Medical University Hospital
Shimotsuke-shi, Tochigi, Japan
St. Luke's International Hospital
Chuo-ku, Tokyo, Japan
Tokyo Medical University Hospital
Shinjuku-Ku, Tokyo, Japan
Medical Corporation Jitai-kai Tachikawa Dermatology Clinic
Tachikawa-shi, Tokyo, Japan
JCHO Tokyo Yamate Medical Center
Shinjuku-ku, Tokyo-to, Japan
Shirasaki Dermatology Clinic
Takaoka-shi, Toyama, Japan
Ohyama Dermatology Clinic
Kumamoto, , Japan
Semigallia
Kuldīga, , Latvia
Health Center 4, Center of Diagnostics
Riga, , Latvia
Health Center 4, Clinic of Dermatology
Riga, , Latvia
Riga 1st Hospital
Riga, , Latvia
Aesthetic dermatology clinic of prof. J. Kisis
Riga, , Latvia
Veseliba un estetika Ltd.
Riga, , Latvia
Outpatient Clinic Adoria
Riga, , Latvia
DermoDent Centrum Medyczne Aldona Czajkowska Rafal Czajkowski, s.c.
Osielsko, Kuyavian-Pomeranian Voivodeship, Poland
Krakowskie Centrum Medyczne Sp. z o.o.
Krakow, Lesser Poland Voivodeship, Poland
Dermedic Jacek Zdybski
Ostrowiec Swietokrzyski, Lower Silesian Voivodeship, Poland
Cityclinic Przychodnia lekarsko psychologiczna Matusiak sp.p
Wroclaw, Lower Silesian Voivodeship, Poland
Centrum Columbus
Wroclaw, Lower Silesian Voivodeship, Poland
Luxderm Specjalistyczny Gabinet Dermatologiczny Dorota Krasowska
Lublin, Lublin Voivodeship, Poland
MICS Centrum Medyczne Warszawa
Warsaw, Masovian Voivodeship, Poland
Klinika Reuma Park Sp. z o.o. sp. k. | Centrum Medyczne Reuma Park
Warsaw, Masovian Voivodeship, Poland
ETG Warszawa - PPDS
Warsaw, Masovian Voivodeship, Poland
Klinika Ambroziak Dermatologia
Warsaw, Masovian Voivodeship, Poland
Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
Rzeszów, Podkarpackie Voivodeship, Poland
ClinicMed Daniluk, Nowak Spolka Komandytowa
Bialystok, Podlaskie Voivodeship, Poland
Centrum Badan Klinicznych Pi-house Sp. Z O. O.
Gdansk, Pomeranian Voivodeship, Poland
Ambulatorium Sp. z o.o. | Elblag, Poland
Elblag, Warmian-Masurian Voivodeship, Poland
NZOZ Holsamed-Oddział Libero
Katowice, , Poland
ETYKA Osrodek Badan Klinicznych
Olsztyn, , Poland
Twoja Przychodnia - Szczecinskie Centrum Medyczne
Szczecin, , Poland
Royalderm Agnieszka Nawrocka
Warsaw, , Poland
Centrum Terapii Współczesnej J.M. Jasnorzewska S.K.A.
Lodz, Łódź Voivodeship, Poland
Dermoklinika-Centrum Medyczne s.c
Lodz, Łódź Voivodeship, Poland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site Contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site Contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Site contact
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Click here for more information about this trial in easy-to-understand language, including a Plain Language Summary of the results if the trial has been completed.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-512497-10-00
Identifier Type: CTIS
Identifier Source: secondary_id
jRCT2011250014
Identifier Type: REGISTRY
Identifier Source: secondary_id
TAK-279-PsO-3004
Identifier Type: -
Identifier Source: org_study_id